Previously he was in practice at the Emory Clinic for six years. In addition to general Endocrinology, his practice focuses on metabolic risks for cardiovascular disease and endocrine disease in transplant patients. Previously, he was part of the faculty at Emory University School of Medicine.
His faculty association was with both the Division of Endocrinology and the Division of Arteriosclerosis and Lipid Metabolism. Currently, he is also associated with the Fuqua Heart Center at Piedmont Hospital as an investigator focusing on diabetes and cardiovascular disease.
Prior to his association with Piedmont Hospital, he was a National Institute of Health investigator at Emory University who received a Physician Scientist Award focused on the regulation of gene expression by insulin in primary hepatocyte and adipocyte cultures.
His current investigations at Piedmont Hospital continue his research support through the National Institute of Health. He is the diabetes principal investigator for the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. The trial hopes to define optimal strategies for the management of active coronary artery disease in the patients with Type 2 Diabetes.
Within his practice he is involved in numerous clinical trials related to the treatment of both type 1 and type 2 diabetes, the treatment of combined dyslipidemia, the treatment of hypercholesterolemia, and treatments to improve insulin sensitivity and reduce cardiovascular risks. He has published papers in all of these areas